Lotiglipron
Sources
registry, as of 2024-08-09Stale
https://clinicaltrials.gov/study/NCT05671653
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range. Overall status TERMINATED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 32. Conditions Obesity. Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide. The effect of these GLP-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. The effect of chronic PF-0
ClinicalTrials.gov NCT05671653 protocol and results modules
registry, as of 2024-11-15Stale
https://clinicaltrials.gov/study/NCT05788328
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants. Overall status TERMINATED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 16. Conditions Healthy. The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants. This study also aims to collect data on safety and how tolerable the study medi
ClinicalTrials.gov NCT05788328 protocol and results modules
registry, as of 2024-09-23Stale
https://clinicaltrials.gov/study/NCT05745701
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 16. Conditions Healthy. This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants. The 3 stud
ClinicalTrials.gov NCT05745701 protocol and results modules
registry, as of 2024-08-01Stale
https://clinicaltrials.gov/study/NCT05579977
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity. Overall status TERMINATED. Phases PHASE2. Lead sponsor Pfizer. Enrollment 902. Conditions Diabetes Mellitus; Obesity. The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metf
ClinicalTrials.gov NCT05579977 protocol and results modules
registry, as of 2024-08-12Stale
https://clinicaltrials.gov/study/NCT05158244
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 34. Conditions Type 2 Diabetes Mellitus. This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the investigational product or placebo every day for 42 days. The purpose of the study is to evaluate the s
ClinicalTrials.gov NCT05158244 protocol and results modules
registry, as of 2024-08-09Stale
https://clinicaltrials.gov/study/NCT05677867
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 20. Conditions Overweight; Obesity. The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese. All study participants will receive a total of 2 single
ClinicalTrials.gov NCT05677867 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05671653
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in
NCT05671653 description or intervention text